Physician profile
Amy Cool
NPI 1649492844
$1,010.75
in general payments reported to CMS, 2019-2025
22 companies · $141 in 2025
The $141 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $202 · 2021: $153 · 2022: $66.86 · 2023: $120 · 2024: $64.83 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $134.57 | 2019-2023 | Menveo, Bexsero, Pediarix |
| Pfizer INC. | $90.93 | 2023-2025 | |
| Neos Therapeutics, LP | $84.82 | 2019-2021 | |
| Biogen, INC. | $72.06 | 2019 | |
| Seqirus USA INC | $69.52 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $68.22 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.96 | 2020 | |
| Adlon Therapeutics L.P. | $61.53 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $56.43 | 2021-2024 | Qelbree, Qelbree |
| Kaleo, INC. | $42.46 | 2021 | |
| Merck Sharp & Dohme LLC | $35.99 | 2019-2022 | |
| Sanofi Pasteur INC. | $32.94 | 2019-2023 | |
| Shire North American Group INC | $28.43 | 2019 | |
| Corium, LLC | $26.68 | 2023 | Azstarys |
| Verrica Pharmaceuticals INC. | $26.19 | 2024 | Ycanth |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.28 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.19 | 2019 | |
| Collegium Pharmaceutical, INC. | $18.05 | 2025 | Jornay Pm |
| Novo Nordisk INC | $16.46 | 2025 | Wegovy |
| Tris Pharma INC | $15.66 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.10 | 2025 | Relexxii |
| Teva Pharmaceuticals USA, INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.